← Eichor
Condition: Nephritis Lupus Synced from ClinicalTrials.gov · July 30, 2026

Recruiting studies: Nephritis Lupus

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Det
Phase N/A · 1 location(s) · National Institute of Arthritis and Musculoskeletal and Skin · NCT05567198A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
Phase 1/Phase 2 · 1 location(s) · Children's Hospital of Philadelphia · NCT06839976Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06585514Lupus Landmark Study: A Prospective Registry and Biorepository
Phase N/A · 25 location(s) · Lupus Research Alliance · NCT05934149Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children
Phase 3 · 1 location(s) · Guangzhou Women and Children's Medical Center · NCT06904729A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07123519A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Phase 1/Phase 2 · 18 location(s) · AstraZeneca · NCT06897930Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients
Phase N/A · 1 location(s) · Sohag University · NCT06631404High Quality Evidence of Chinese Lupus Nephritis (HELP)
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT03001973Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
NA · 1 location(s) · Tongji Hospital · NCT06902844Disease Activity Biomarkers in Patients With Systemic Lupus Erythematosus
Phase N/A · 1 location(s) · Cliniques universitaires Saint-Luc- Université Catholique de · NCT05443516Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients
Phase N/A · 1 location(s) · Sohag University · NCT07017868Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)
Phase N/A · 1 location(s) · Stefan Lujinschi · NCT07575347The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
Phase 1 · 1 location(s) · Nanjing University School of Medicine · NCT06285279A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephrit
Phase 2 · 17 location(s) · Hoffmann-La Roche · NCT07598396Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycopheno
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT04702256Wellness & Workforce Solution for Lupus/Lupus Nephritis
NA · 1 location(s) · Morehouse School of Medicine · NCT06217107A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatm
Phase 3 · 14 location(s) · Viatris Innovation GmbH · NCT07201129The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
Phase 2 · 19 location(s) · Children's Hospital Medical Center, Cincinnati · NCT05538208Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Di
Phase 1/Phase 2 · 2 location(s) · M.D. Anderson Cancer Center · NCT06434363CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
EARLY_Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07586267LUPKYNIS Drug-use Results Survey
Phase N/A · 1 location(s) · Otsuka Pharmaceutical Co., Ltd. · NCT07053891SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523542Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells
Phase 2 · 1 location(s) · Red de Terapia Celular · NCT03673748Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Phase 1 · 18 location(s) · Regeneron Pharmaceuticals · NCT06975787A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I
Phase 2 · 96 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07015983Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)
Phase 4 · 8 location(s) · Peking Union Medical College Hospital · NCT07719140RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic
Phase 1/Phase 2 · 23 location(s) · Cabaletta Bio · NCT06121297A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Phase N/A · 1 location(s) · Kyverna Therapeutics · NCT07403188
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.